Device Orthopedics/Orthopedic Surgery

Optimesh Expandable Interbody Fusion System

Payments companies reported to CMS as associated with Optimesh Expandable Interbody Fusion System. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$1.6Massociated payments (2023-2025)
805clinicians with associated payments
2companies reporting

By year

2023 $590K
2024 $489K
2025 $487K

Payments reported as associated with Optimesh Expandable Interbody Fusion System, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Neurological Surgery $812K
Orthopaedic Surgery of The Spine $477K
Orthopaedic Surgery $195K
Physician Assistant $11K
Surgical $3,158
Neurology (Psychiatry & Neurology) $2,161

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Optimesh Expandable Interbody Fusion System

These are the largest totals companies reported as associated with Optimesh Expandable Interbody Fusion System. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Betsy Grunch Gainesville, GA Neurological Surgery $110,285.88
Clifford Tribus Madison, WI Orthopaedic Surgery $98,532.50
Michael Wang Miami, FL Neurological Surgery $98,206.83
Samuel Joseph Safety Harbor, FL Orthopaedic Surgery of The Spine $80,523.91
Sanjay Konakondla Danville, PA Neurological Surgery $73,914.81
Ali Hazama Syracuse, NY Neurological Surgery $70,572.30
Daniel Wells Knoxville, TN Orthopaedic Surgery of The Spine $70,543.40
Jeffrey Moore Oklahoma City, OK Orthopaedic Surgery of The Spine $65,579.89
Michael Song Reno, NV Neurological Surgery $52,744.48
Christopher Yeung Phoenix, AZ $48,192.59

Prescribed Optimesh Expandable Interbody Fusion System?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.